PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21824498-4 2011 Recently, we reported that MK591, a specific inhibitor of 5-LOX activity, induces apoptosis in prostate cancer cells without inhibition of Akt, or ERK, two well-characterized regulators of pro-survival mechanisms, suggesting the existence of an Akt and ERK-independent survival mechanism in prostate cancer cells regulated by 5-LOX. MK 0591 27-32 arachidonate 5-lipoxygenase Homo sapiens 58-63 21824498-4 2011 Recently, we reported that MK591, a specific inhibitor of 5-LOX activity, induces apoptosis in prostate cancer cells without inhibition of Akt, or ERK, two well-characterized regulators of pro-survival mechanisms, suggesting the existence of an Akt and ERK-independent survival mechanism in prostate cancer cells regulated by 5-LOX. MK 0591 27-32 arachidonate 5-lipoxygenase Homo sapiens 326-331 9041233-2 1997 The aim of this study was to determine whether inhibition of LT biosynthesis with a 5-lipoxygenase inhibitor (MK-591) induces remission in patients with mild to moderate UC. MK 0591 110-116 arachidonate 5-lipoxygenase Homo sapiens 84-98 19906484-1 2010 MK591 is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. MK 0591 0-5 arachidonate 5-lipoxygenase Homo sapiens 74-79 9507210-7 1998 Administration of the 5-lipoxygenase (5-LO) inhibitor, MK-0591, at doses sufficient to inhibit glomerular LTB4 synthesis also increased iNOS mRNA. MK 0591 55-62 arachidonate 5-lipoxygenase Homo sapiens 22-36 10531413-7 1999 This AA-induced Ca(2+) mobilization, as well as the corresponding 5-lipoxygenase translocation and stimulation of LT synthesis, was blocked efficiently by the LT synthesis inhibitor MK0591, the LTB(4) receptor antagonists CP105696 and LY223982, and the LTA(4) hydrolase inhibitor SC57461A. MK 0591 182-188 arachidonate 5-lipoxygenase Homo sapiens 66-80 8033491-0 1994 Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor. MK 0591 64-71 arachidonate 5-lipoxygenase Homo sapiens 75-89 7697951-2 1995 MK-0591 (3-(1((4-chlorophenyl)methyl)-3((1,1-dimethyl-ethyl)thio)-5(quinolin+ ++-2ylmethyl-oxy)-1H-indol-2yl)-2,2-dimethyl-propanoate) exerts its effect by binding to the 5-lipoxygenase activating protein, thereby inhibiting the translocation and activation of 5-lipoxygenase. MK 0591 0-7 arachidonate 5-lipoxygenase Homo sapiens 171-185 7697951-2 1995 MK-0591 (3-(1((4-chlorophenyl)methyl)-3((1,1-dimethyl-ethyl)thio)-5(quinolin+ ++-2ylmethyl-oxy)-1H-indol-2yl)-2,2-dimethyl-propanoate) exerts its effect by binding to the 5-lipoxygenase activating protein, thereby inhibiting the translocation and activation of 5-lipoxygenase. MK 0591 0-7 arachidonate 5-lipoxygenase Homo sapiens 261-275 7822663-0 1995 The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. MK 0591 14-21 arachidonate 5-lipoxygenase Homo sapiens 31-45 7822663-2 1995 We investigated the effect of pretreatment with MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on allergen-induced early asthmatic reactions (EARs) and late asthmatic reactions (LARs), and subsequent airway hyperresponsiveness to histamine. MK 0591 48-55 arachidonate 5-lipoxygenase Homo sapiens 65-79 32313135-10 2020 We found that 5-Lox regulates c-Myc signaling in enzalutamide-resistant prostate cancer cells and inhibition of 5-Lox by Quiflapon/MK591 or shRNA interrupts oncogenic c-Myc signaling and kills ERPC cells by triggering caspase-mediated apoptosis. MK 0591 121-130 arachidonate 5-lipoxygenase Homo sapiens 112-117 32313135-10 2020 We found that 5-Lox regulates c-Myc signaling in enzalutamide-resistant prostate cancer cells and inhibition of 5-Lox by Quiflapon/MK591 or shRNA interrupts oncogenic c-Myc signaling and kills ERPC cells by triggering caspase-mediated apoptosis. MK 0591 131-136 arachidonate 5-lipoxygenase Homo sapiens 112-117 25540201-8 2015 Interestingly, MK591, a specific 5-Lox inhibitor, strongly affects the viability of Myc-overactivated prostate cancer cells and completely blocks their invasive and soft agar colony-forming abilities, but it spares nontransformed cells where expression of 5-Lox is undetectable. MK 0591 15-20 arachidonate 5-lipoxygenase Homo sapiens 33-38 30728896-7 2019 Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential role in the survival of PCSC. MK 0591 69-74 arachidonate 5-lipoxygenase Homo sapiens 34-48 30728896-7 2019 Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential role in the survival of PCSC. MK 0591 69-74 arachidonate 5-lipoxygenase Homo sapiens 50-55 30728896-7 2019 Here we report that inhibition of 5-lipoxygenase (5-Lox) by shRNA or MK591 dramatically kills PCSC by inducing apoptosis, suggesting that 5-Lox plays an essential role in the survival of PCSC. MK 0591 69-74 arachidonate 5-lipoxygenase Homo sapiens 138-143 25540201-8 2015 Interestingly, MK591, a specific 5-Lox inhibitor, strongly affects the viability of Myc-overactivated prostate cancer cells and completely blocks their invasive and soft agar colony-forming abilities, but it spares nontransformed cells where expression of 5-Lox is undetectable. MK 0591 15-20 arachidonate 5-lipoxygenase Homo sapiens 256-261